心源性和非心源性脑梗死阿替普酶溶栓对比研究

Comparative Study of Alteplase Thrombolysis in Cardiogenic and Non-cardiogenic Cerebral Infarction

目的研究心源性和非心源性脑梗死疾病中阿替普酶溶栓治疗的疗效。方法方便选取2019年3月—2020年6月该院收治的52例脑梗死患者作为该次研究对象,24例为心源性脑梗死患者,28例非心源性脑梗死患者,两组患者均予以阿替普酶溶栓治疗,对比两组患者的神经功能缺损情况、患者的日常生活活动能力以及患者的不良反应发生率。结果非心源性脑梗死组患者治疗24 h后和治疗7 d后的神经功能缺损(NIHSS)评分均低于心源性脑梗死组患者,差异有统计学意义(t=2.139、3.232,P<0.05);非心源性脑梗死组患者治疗24 h后和治疗7 d后的日常生活活动能力(BI)评分均高于心源性脑梗死组患者,差异有统计学意义(t=2.382、4.622,P<0.05);非心源性脑梗死组患者的不良反应发生率7.14%比心源性脑梗死组患者33.33%低,差异有统计学意义(χ^(2)=4.145,P<0.05)。结论将阿替普酶用于心源性和非心源性脑梗死患者的治疗中,相比心源性脑梗死患者,阿替普酶治疗非心源性脑梗死患者的效果更好,能有效改善患者的神经功能缺损情况,且治疗后不良反应更少,安全性高。

Objective To study the efficacy of alteplase thrombolytic therapy in cardiogenic and non-cardiogenic cerebral infarction diseases.Methods Conveniently select Fifty-two patients with cerebral infarction admitted to the hospital from March 2019 to June 2020 were selected as the study objects,24 patients with cardiogenic cerebral infarction,28 patients with non-cardiogenic cerebral infarction,both groups of patients Alteplase was given thrombolytic therapy,and the neurological deficits,the patients'activities of daily living and the incidence of adverse reactions of the two groups of patients were compared.Results The neurological deficit(NIHSS)scores of patients in the non-cardiogenic cerebral infarction group were lower than those in the cardiogenic cerebral infarction group after 24 h of treatment and 7 d after treatment,and the difference was statistically significant(t=2.139,3.232,P<0.05);The activity of daily living(BI)scores of patients in the non-cardiogenic cerebral infarction group after 24 h of treatment and 7 d after treatment were higher than those in the cardiogenic cerebral infarction group,and the difference was statistically significant(t=2.382,4.622,P<0.05);the incidence of adverse reactions in the non-cardiogenic cerebral infarction group was 7.14%,which was lower than 33.33%in the cardiogenic cerebral infarction group,and the difference was statistically significant(χ^(2)=4.145,P<0.05).Conclusion Alteplase is used in the treatment of patients with cardiogenic and non-cardiogenic cerebral infarction.Compared with patients with cardiogenic cerebral infarction,alteplase is more effective in the treatment of patients with non-cardiogenic cerebral infarction,which can effectively improve the patient's neurological deficits,with fewer adverse reactions after treatment,and high safety.